Alzheimer's fail crushes small biotech's share price to nearly penny stock
Alzheimer’s research has wiped out another biotech’s market cap.
Synaptogenix, a small startup based out of New York, reported a Phase II Alzheimer’s fail Friday …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
